Research peptides

CJC-1295 + GHRP-2 Dosage: The Blend, Protocol and Calculator

Q: Is CJC-1295 and GHRP-2 legal?

Neither has FDA approval. Both are sold as research chemicals, not legally marketed for human use in the US. Both are named in the WADA Prohibited List as growth hormone releasing factors and secretagogues, prohibited at all times in sport.

CJC-1295 and GHRP-2 dosage: the common 10 mg blend vial two real sources describe, reconstitution math, why the pair is used, and side effects.

Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

Published September 28, 2026

The short version

CJC-1295 (no-DAC) and GHRP-2 are two growth-hormone-axis research peptides commonly sold together in one 10 mg blend vial, 5 mg of each. Dosing sites describe 100-200 mcg of each peptide per injection, with a fasted pre-bed injection as the common timing. This is common practice, not a dose any trial has tested for this combination, and no published human study has given the two together.

The common product is a single 10 mg vial: 5 mg CJC-1295 (no-DAC) plus 5 mg GHRP-2, a 1:1 ratio.
Dosing sites describe 100-200 mcg of each peptide per injection, with a fasted pre-bed dose - not trial-tested as a pairing.
No published human trial has tested CJC-1295 and GHRP-2 given together, at any dose.
Reconstitution and injection-volume math belongs on a calculator, not a guess.

CJC-1295 (no-DAC) and GHRP-2 are two growth-hormone-axis research peptides frequently sold and dosed as a pair, usually from one blended vial. Neither has an approved dose, because neither has an approved product, and no published human trial has tested the two together. This page covers what dosing sources describe for the blend, the reconstitution arithmetic, why the pairing is used, and what remains untested. For each compound on its own, see the CJC-1295 guide and the GHRP-2 guide.

US legal status - Research use only

Neither CJC-1295 nor GHRP-2 has an FDA-approved product. Both are sold as research chemicals, not legally marketed for human use.

AU legal status - Not on the ARTG

Both are named in the Poisons Standard (Appendix D) - prescription only, and neither is on the ARTG.

Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.

CJC-1295 and GHRP-2 dosage: the common protocol

Two independent dosing-guide sites describe how the pair is dosed, and a vendor lists the blend itself.

Peptides.ID’s Mod GRF and GHRP-2 protocol describes a 1:1 blend. Its example is 5 mg of each in a 10 mg vial, reconstituted with 2.0 mL of bacteriostatic water. The dose is 100 mcg of each peptide as standard or 200 mcg of each at its advanced tier. It is given one to three times a day, post-workout and/or before bed on an empty stomach, over a 12-16 week cycle.
The Peptide Catalog’s CJC-1295 guide, a separate site, pairs 200 mcg of CJC-1295 (no-DAC) with 100-200 mcg of GHRP-2 in one evening injection, fasted. The schedule is five days on and two off, for 8 weeks followed by 8 weeks off.
The vendor Core Peptides lists the blend as CJC-1295 (no-DAC) 5 mg plus GHRP-2 5 mg in one 10 mg vial, the same 1:1 ratio.

The two dosing sources agree on 100-200 mcg of GHRP-2 per injection, on CJC-1295 at up to 200 mcg, and on a fasted pre-bed injection. They disagree on how many injections a day and on cycle length (8 weeks on and 8 off in one, 12-16 weeks in the other), so this page gives both. Neither source is a clinical or regulatory reference. Both describe current community practice, not a trial-established dose.

CJC-1295 (no-DAC) + GHRP-2 (1:1) 10 mg vial

Water added	Concentration	1 unit =	200 mcg	300 mcg	400 mcg
2 mL water	5 mg/mL	50 mcg	4 units	6 units	8 units

Units on a U-100 insulin syringe (100 units = 1 mL), to the nearest half unit. 0.2-0.4 mg of the 1:1 blend is 100-200 mcg of each peptide, the per-peptide range Peptides.ID describes; The Peptide Catalog pairs 200 mcg CJC-1295 with 100-200 mcg GHRP-2, which in a 1:1 vial matches the top of that range. 2 mL of water is the volume Peptides.ID gives. Neither site is a clinical or regulatory source.

Why CJC-1295 and GHRP-2 are paired

The two compounds act on different receptors that both feed into a pituitary growth-hormone pulse.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It acts on the pituitary’s GHRH receptor, which a published trial of the with-DAC form measured directly Teichman 2006 - Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805., in the references below. GHRP-2 acts on a separate receptor, the ghrelin receptor (GHS-R1a). A published diagnostic-dose study in healthy adults and growth-hormone-deficient patients measured that one Chihara 2007 - Chihara K, Shimatsu A, Hizuka N et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27., in the references below.

Peptides.ID says the no-DAC form gives prolonged receptor stimulation that mimics natural GHRH, and that GHRP-2 amplifies the pituitary response through ghrelin mimicry. It presents the pair as synergistic. That is a mechanism argument from one source, not evidence that the combination has been tested in people.

What no published trial has tested

Each compound has its own published human trial data, and neither trial used anything like the blend protocol above.

A randomised trial in healthy adults Teichman 2006 - Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805., in the references below tested CJC-1295 with-DAC alone, as single or repeated subcutaneous doses of 30 or 60 mcg/kg. That is a different form, dose unit and schedule from the daily no-DAC blend described here.
GHRP-2’s published human studies gave it alone, as a single monitored intravenous diagnostic dose rather than a repeated subcutaneous protocol Chihara 2007 - Chihara K, Shimatsu A, Hizuka N et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27., in the references below.

Full detail on each is on their own dosing pages: CJC-1295 dosage and GHRP-2 dosage.

No published human study has given CJC-1295 and GHRP-2 together, in any dose, route or schedule. The blend protocol above comes entirely from dosing guides describing current practice.

Side effects of each component

At the doses each trial tested, neither published study reported a serious adverse reaction directly attributed to the compound. The CJC-1295 with-DAC trial Teichman 2006 - Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805., in the references below reported no serious adverse reactions. The GHRP-2 diagnostic-dose study Chihara 2007 - Chihara K, Shimatsu A, Hizuka N et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27., in the references below was a single-injection clinical test, not designed to capture longer-term side effects. Full side-effect detail for each compound is on its own page: the CJC-1295 guide and the GHRP-2 guide.

None of that is safety data for the blend. Neither compound has long-term human safety data, and no trial has tested them together at this dose and schedule. The combination carries risks, including unknown interaction effects, that this page cannot quantify because no source has measured them. A vial bought outside the trial system carries no verified content, purity or actual concentration for either peptide.

Is CJC-1295 and GHRP-2 legal?

Neither compound has FDA approval, in any form. Both are sold as research chemicals rather than legally marketed human drugs. Both are named in the current WADA Prohibited List as growth hormone releasing factors and secretagogues, prohibited at all times in sport. Combining them into one vial does not change either compound’s regulatory status.

See each compound’s own page for jurisdiction-specific detail: CJC-1295 and GHRP-2. For how US law treats research-use-only peptides generally, see research peptides and the law.

Common questions

What is the usual CJC-1295 and GHRP-2 dosage?

Two dosing-guide sites describe 100-200 mcg of each peptide per injection (200-400 mcg of a 1:1 blend), given subcutaneously on an empty stomach. Both name a pre-bed injection. They differ on frequency and cycle length. One describes a single evening dose five days a week for 8 weeks, then 8 weeks off. The other describes one to three doses a day for 12-16 weeks. This is common practice reported by dosing guides, not a dose any trial has tested for this combination.

What comes in a CJC-1295 and GHRP-2 blend vial?

The product most often sold is a single 10 mg vial holding 5 mg of CJC-1295 (no-DAC) and 5 mg of GHRP-2, a 1:1 ratio. One reconstitution and one injection delivers both peptides.

Why are CJC-1295 and GHRP-2 used together?

CJC-1295 is a GHRH-receptor analogue. GHRP-2 acts on a separate receptor, the ghrelin receptor (GHS-R1a). Sources describing the blend say pairing the two produces a larger growth-hormone response than either alone. That is a mechanism argument from those sources, not a trial finding for this blend.

Has the CJC-1295 and GHRP-2 combination been tested in a clinical trial?

No. Each compound has separate published human trial data on its own (see the individual dosing pages), but no published human trial has given the two together. The common protocol below comes from dosing guides describing current practice, not a controlled study.

How do I work out reconstitution and injection volume for the blend?

That depends on the specific vial: its total mg content and how much diluent was added. This page cannot know either. Use the dosage calculator to work through the arithmetic for your own vial.

What are the side effects of combining CJC-1295 and GHRP-2?

The published trials of each compound alone reported no serious adverse reactions directly attributed to it. Those were small, short, clinically monitored studies at doses different from the blend protocol. No published trial has looked at side effects of the two together, so the combination has no dedicated human safety data.

References (5 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

1.Teichman SL, Neale A, Lawrence B et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.Randomised trialPMID 16352683
2.Chihara K, Shimatsu A, Hizuka N et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27.Clinical trialPMID 17609397
3.Peptides.ID’s Mod GRF and GHRP-2 protocol- peptides.idother
4.The Peptide Catalog’s CJC-1295 guide- thepeptidecatalog.comother
5.Core Peptides- corepeptides.comother